Skip to main content

Articles

Page 18 of 39

  1. Integrins are a family of transmembrane glycoprotein signaling receptors that can transmit bioinformation bidirectionally across the plasma membrane. Integrin αIIbβ3 is expressed at a high level in platelets a...

    Authors: Jiansong Huang, Xia Li, Xiaofeng Shi, Mark Zhu, Jinghan Wang, Shujuan Huang, Xin Huang, Huafeng Wang, Ling Li, Huan Deng, Yulan Zhou, Jianhua Mao, Zhangbiao Long, Zhixin Ma, Wenle Ye, Jiajia Pan…
    Citation: Journal of Hematology & Oncology 2019 12:26
    Content type: Review Published on:

  2. Mechanisms by which Smac mimetics (SMs) interact with proteasome inhibitors (e.g., bortezomib) are largely unknown, particularly in multiple myeloma (MM), a disease in which bortezomib represents a mainstay of...

    Authors: Liang Zhou, Yu Zhang, Yun Leng, Yun Dai, Maciej Kmieciak, Lora Kramer, Kanika Sharma, Yan Wang, William Craun and Steven Grant
    Citation: Journal of Hematology & Oncology 2019 12:25
    Content type: Research Published on:

  3. The original article [1] contains two errors in the MRD Testing sub-section of the Methods:

    Authors: Chen-Hua Yan, Yu Wang, Jing-Zhi Wang, Yu-Hong Chen, Yao Chen, Feng-rong Wang, Yu-Qian Sun, Xiao-Dong Mo, Wei Han, Huan Chen, Xiao-hui Zhang, Lan-Ping Xu, Kai-Yan Liu and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2019 12:24
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2016 9:87

  4. The expression of CYP4Z1 and the pseudogene CYP4Z2P has been shown to be specifically increased in breast cancer by our group and others. Additionally, we previously revealed the roles of the competitive endog...

    Authors: Lufeng Zheng, Qianqian Guo, Chenxi Xiang, Shijia Liu, Yuzhang Jiang, Lanlan Gao, Haiwei Ni, Ting Wang, Qiong Zhao, Hai Liu, Yingying Xing, Yaohui Wang, Xiaoman Li and Tao Xi
    Citation: Journal of Hematology & Oncology 2019 12:23
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:109

  5. There is a dearth of accurate information about patterns of mortality of lymphoid neoplasms and temporal trends in China. In this nationwide mortality study, we aimed to assess the mortality of lymphoma and my...

    Authors: Weiping Liu, Jiangmei Liu, Yuqin Song, Xiaopei Wang, Maigeng Zhou, Lijun Wang, Jun Ma and Jun Zhu
    Citation: Journal of Hematology & Oncology 2019 12:22
    Content type: Research Published on:

  6. Ring finger proteins (RNFs) were involved in carcinogenesis. Here, we aimed to explore the detailed mechanism of RNF128 in the progression of melanoma.

    Authors: Chuan-Yuan Wei, Meng-Xuan Zhu, Yan-Wen Yang, Peng-Fei Zhang, Xuan Yang, Rui Peng, Chao Gao, Jia-Cheng Lu, Lu Wang, Xin-Yi Deng, Nan-Hang Lu, Fa-Zhi Qi and Jian-Ying Gu
    Citation: Journal of Hematology & Oncology 2019 12:21
    Content type: Research Published on:

  7. Tumor microenvironment (TME) is a complex environment containing tumor cells, tumor-associated macrophages (TAMs), interstitial cells, and non-cellular components. Epithelial–mesenchymal transition (EMT), as a...

    Authors: Xiaobin Lin, Shuyi Wang, Min Sun, Chunxiao Zhang, Chen Wei, Chaogang Yang, Rongzhang Dou, Qing Liu and Bin Xiong
    Citation: Journal of Hematology & Oncology 2019 12:20
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:122

  8. Increasing evidence has demonstrated that mesenchymal stem cells (MSCs) play a role in the construction of tumor microenvironments. Co-culture between tumor cells and MSCs provides an easy and useful platform ...

    Authors: Jing Li, Yajing Hao, Wenzhe Mao, Xiaowei Xue, Pengchao Xu, Lihui Liu, Jiao Yuan, Dongdong Zhang, Na Li, Hua Chen, Lin Zhao, Zhao Sun, Jianjun Luo, Runsheng Chen and Robert Chunhua Zhao
    Citation: Journal of Hematology & Oncology 2019 12:19
    Content type: Research Published on:

  9. Gastric cancer (GC) is a common cancer in Asia and currently lacks a targeted therapy approach. Mesothelin (MSLN) has been reported to be expressed in GC tissue and could be targeted by chimeric antigen recept...

    Authors: Jiang Lv, Ruocong Zhao, Di Wu, Diwei Zheng, Zhiping Wu, Jingxuan Shi, Xinru Wei, Qiting Wu, Youguo Long, Simiao Lin, Suna Wang, Zhi Wang, Yang Li, Yantao Chen, Qing He, Suimin Chen…
    Citation: Journal of Hematology & Oncology 2019 12:18
    Content type: Research Published on:

  10. The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or rela...

    Authors: Juanjuan Zhao, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2019 12:17
    Content type: Review Published on:

  11. The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, t...

    Authors: Jian Li, Ying Yuan, Fan Yang, Yi Wang, Xu Zhu, Zhenghang Wang, Shu Zheng, Desen Wan, Jie He, Jianping Wang, Yi Ba, Chunmei Bai, Li Bai, Wei Bai, Feng Bi, Kaican Cai…
    Citation: Journal of Hematology & Oncology 2019 12:16
    Content type: Review Published on:

  12. The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual...

    Authors: Delong Liu, Juanjuan Zhao, Yongping Song, Xiaofeng Luo and Ting Yang
    Citation: Journal of Hematology & Oncology 2019 12:15
    Content type: Review Published on:

  13. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks effective therapeutic targets. Sperm-associated antigen 5 (SPAG5) is a mitotic spindle-associated protein that is involved...

    Authors: Ming Li, Anqi Li, Shuling Zhou, Hong Lv and Wentao Yang
    Citation: Journal of Hematology & Oncology 2019 12:14
    Content type: Research Published on:

  14. Allogeneic hematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adopt...

    Authors: Theresa Kaeuferle, Ramona Krauss, Franziska Blaeschke, Semjon Willier and Tobias Feuchtinger
    Citation: Journal of Hematology & Oncology 2019 12:13
    Content type: Review Published on:

  15. Adenylate kinase 4 (AK4) has been identified as a biomarker of metastasis in lung cancer. However, the impacts of AK4 on metabolic genes and its translational value for drug repositioning remain unclear.

    Authors: Yi-Hua Jan, Tsung-Ching Lai, Chih-Jen Yang, Yuan-Feng Lin, Ming-Shyan Huang and Michael Hsiao
    Citation: Journal of Hematology & Oncology 2019 12:12
    Content type: Research Published on:

  16. Leiomyosarcoma (LMS) is one of the most frequent soft tissue sarcoma subtypes and is characterized by a consistent deregulation of the PI3K/mTOR pathway. Cancer stem cells (CSCs) have been poorly studied in so...

    Authors: Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, Carlo Lucchesi, Scott R. Daigle, Elodie Richard, Audrey Laroche-Clary, François Le Loarer and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2019 12:11
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:116

  17. Cell-cell interactions maintain tissue homeostasis and contribute to dynamic alteration of the tumor microenvironment (TME). Communication between cancer and host cells not only promotes advanced disease aggre...

    Authors: Wei-Lun Hwang, Hsin-Yi Lan, Wei-Chung Cheng, Shih-Ching Huang and Muh-Hwa Yang
    Citation: Journal of Hematology & Oncology 2019 12:10
    Content type: Research Published on:

  18. Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit), mitosis-related kinase Aurora B, and chroni...

    Authors: Yongkun Sun, Lin Yang, Xuezhi Hao, Yutao Liu, Jinwen Zhang, Zhiqiang Ning and Yuankai Shi
    Citation: Journal of Hematology & Oncology 2019 12:9
    Content type: Research Published on:

  19. Long non-coding RNAs (lncRNAs) have emerged as a novel class of RNA due to its diverse mechanism in cancer development and progression. However, the role and expression pattern of lncRNAs in molecular subtypes...

    Authors: Alva Rani James, Michael P. Schroeder, Martin Neumann, Lorenz Bastian, Cornelia Eckert, Nicola Gökbuget, Jutta Ortiz Tanchez, Cornelia Schlee, Konstandina Isaakidis, Stefan Schwartz, Thomas Burmeister, Arend von Stackelberg, Michael A. Rieger, Stefanie Göllner, Martin Horstman, Martin Schrappe…
    Citation: Journal of Hematology & Oncology 2019 12:8
    Content type: Research Published on:

  20. JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I stud...

    Authors: Bixia Tang, Xieqiao Yan, Xinan Sheng, Lu Si, Chuanliang Cui, Yan Kong, Lili Mao, Bin Lian, Xue Bai, Xuan Wang, Siming Li, Li Zhou, Jiayi Yu, Jie Dai, Kai Wang, Jinwei Hu…
    Citation: Journal of Hematology & Oncology 2019 12:7
    Content type: Research Published on:

  21. There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outc...

    Authors: Narendranath Epperla, Kwang W. Ahn, Carlos Litovich, Sairah Ahmed, Minoo Battiwalla, Jonathon B. Cohen, Parastoo Dahi, Nosha Farhadfar, Umar Farooq, Cesar O. Freytes, Nilanjan Ghosh, Bradley Haverkos, Alex Herrera, Mark Hertzberg, Gerhard Hildebrandt, David Inwards…
    Citation: Journal of Hematology & Oncology 2019 12:6
    Content type: Research Published on:

  23. Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatme...

    Authors: Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna, Paola Omedè, Antonio Palumbo, Sara Bringhen, Lorenzo De Paoli, Enrica Martino, Alessandra Larocca, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea…
    Citation: Journal of Hematology & Oncology 2019 12:4
    Content type: Research Published on:

  24. Abnormal expression of long non-coding RNAs (lncRNAs) has been found in almost all human tumors, providing numerous potential diagnostic biomarkers, prognostic biomarkers, and therapeutic targets.

    Authors: Mu Xu, Xiaoxiang Chen, Kang Lin, Kaixuan Zeng, Xiangxiang Liu, Xueni Xu, Bei Pan, Tao Xu, Li Sun, Bangshun He, Yuqin Pan, Huiling Sun and Shukui Wang
    Citation: Journal of Hematology & Oncology 2019 12:3
    Content type: Research Published on:

  25. Multiple myeloma (MM) is a clonal plasma cell malignancy associated with osteolytic bone disease. Recently, the role of MM-derived exosomes in the osteoclastogenesis has been demonstrated although the underlyi...

    Authors: Stefania Raimondo, Laura Saieva, Emanuela Vicario, Marzia Pucci, Denise Toscani, Mauro Manno, Samuele Raccosta, Nicola Giuliani and Riccardo Alessandro
    Citation: Journal of Hematology & Oncology 2019 12:2
    Content type: Research Published on:

  26. Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly s...

    Authors: Kamal Chamoun, Hagop Kantarjian, Rami Atallah, Graciela Nogueras Gonzalez, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan Kadia, Naveen Pemmaraju, Elias Jabbour…
    Citation: Journal of Hematology & Oncology 2019 12:1
    Content type: Research Published on:

  27. Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistan...

    Authors: Jorge E. Cortes, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi K. Kota, Philippe Rousselot and Carlo Gambacorti-Passerini
    Citation: Journal of Hematology & Oncology 2018 11:143
    Content type: Review Published on:

  28. The immune system is the hard-wired host defense mechanism against pathogens as well as cancer. Five years ago, we pondered the question if the era of cancer immunotherapy was upon us (Li et al., Exp Hem Oncol...

    Authors: Zihai Li, Wenru Song, Mark Rubinstein and Delong Liu
    Citation: Journal of Hematology & Oncology 2018 11:142
    Content type: Review Published on:

  29. Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directe...

    Authors: Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Nan Yang, Ru Zhang, Hui Zhang, Ying Shen…
    Citation: Journal of Hematology & Oncology 2018 11:141
    Content type: Research Published on:

  31. The study aims to present the effect of PIK3CA E542K and E545K mutations on glucose metabolism and proliferation and identify their underlying mechanisms in cervical cancer.

    Authors: Wei Jiang, Tiancong He, Shuai Liu, Yingying Zheng, Libing Xiang, Xuan Pei, Ziliang Wang and Huijuan Yang
    Citation: Journal of Hematology & Oncology 2018 11:139
    Content type: Research Published on:

  32. There is no convincing data on the trends of hospitalizations, mortality, cost, and demographic variations associated with inpatient admissions for gastric cancer in the USA. The aim of this study was to use a...

    Authors: Delong Liu, Dhruv Mehta, Supreet Kaur, Arun Kumar, Kaushal Parikh, Lavneet Chawla, Shanti Patel, Amirta Devi and Aparna Saha
    Citation: Journal of Hematology & Oncology 2018 11:138
    Content type: Research Published on:

  33. Human myeloma cell lines (HMCLs) are widely used for their representation of primary myeloma cells because they cover patient diversity, although not fully. Their genetic background is mostly undiscovered, and...

    Authors: Benoît Tessoulin, Agnès Moreau-Aubry, Géraldine Descamps, Patricia Gomez-Bougie, Sophie Maïga, Alban Gaignard, David Chiron, Emmanuelle Ménoret, Steven Le Gouill, Philippe Moreau, Martine Amiot and Catherine Pellat-Deceunynck
    Citation: Journal of Hematology & Oncology 2018 11:137
    Content type: Research Published on:

  34. Precision radiotherapy, which accurately delivers the dose on a tumor and confers little or no irradiation to the surrounding normal tissue and organs, results in maximum tumor control and decreases the toxici...

    Authors: Man Hu, Liyang Jiang, Xiangli Cui, Jianguang Zhang and Jinming Yu
    Citation: Journal of Hematology & Oncology 2018 11:136
    Content type: Review Published on:

  35. Mesenchymal stromal cells (MSCs) are a promising therapy for preventing chronic Graft-Versus-Host Disease (cGVHD) due to their potent immunomodulatory properties. However, the safety concerns regarding the use...

    Authors: Peilong Lai, Xiaomei Chen, Liyan Guo, Yulian Wang, Xialin Liu, Yan Liu, Tian Zhou, Tian Huang, Suxia Geng, Chengwei Luo, Xin Huang, Suijing Wu, Wei Ling, Xin Du, Chang He and Jianyu Weng
    Citation: Journal of Hematology & Oncology 2018 11:135
    Content type: Research Published on:

  36. Natural-killer/T cell lymphoma (NKTCL) represents the most common subtype of extranodal lymphoma with aggressive clinical behavior. Prevalent in Asians and South Americans, the pathogenesis of NKTCL remains to...

    Authors: Jie Xiong and Wei-Li Zhao
    Citation: Journal of Hematology & Oncology 2018 11:134
    Content type: Review Published on:

  37. FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved ...

    Authors: Mei Wu, Chuntuan Li and Xiongpeng Zhu
    Citation: Journal of Hematology & Oncology 2018 11:133
    Content type: Review Published on:

  38. Currently, the two approved T cell products with chimeric antigen receptors (CAR) are from autologous T cells. These CAR T cells approved for clinical use must be generated on a custom-made basis. This case-by...

    Authors: Juanjuan Zhao, Quande Lin, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2018 11:132
    Content type: Review Published on:

  39. Recent studies have revealed that non-coding regions comprise the vast majority of the human genome and long non-coding RNAs (lncRNAs) are a diverse class of non-coding RNAs that has been implicated in a varie...

    Authors: Nonthaphat Kent Wong, Chien-Ling Huang, Rashidul Islam and Shea Ping Yip
    Citation: Journal of Hematology & Oncology 2018 11:131
    Content type: Review Published on:

  41. This retrospective study was undertaken to determine if the plasma circulating tumor DNA (ctDNA) level and tumor biological features in patients with advanced solid tumors affected the detection of genomic alt...

    Authors: Cathy Zhou, Zilong Yuan, Weijie Ma, Lihong Qi, Angelique Mahavongtrakul, Ying Li, Hong Li, Jay Gong, Reggie R. Fan, Jin Li, Michael Molmen, Travis A. Clark, Dean Pavlick, Garrett M. Frampton, Brady Forcier, Elizabeth H. Moore…
    Citation: Journal of Hematology & Oncology 2018 11:129
    Content type: Research Published on:

  42. POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome still has no standard treatment. On the basis that both POEMS syndrome and myeloma have an underlying plas...

    Authors: Jinhuan Xu, Qiuxiang Wang, Hao Xu, Chaojiang Gu, Lijun Jiang, Jue Wang, Di Wang, Bin Xu, Xia Mao, Jin Wang, Zhiqiong Wang, Yi Xiao, Yicheng Zhang, Chunrui Li and Jianfeng Zhou
    Citation: Journal of Hematology & Oncology 2018 11:128
    Content type: Case report Published on:

  43. Graft-versus-host disease (GVHD) is one of the leading causes of non-relapse mortality and morbidity after allogeneic hematopoietic stem cell transplantation (allo-HCT).

    Authors: Florent Malard, Myriam Labopin, Christina Cho, Didier Blaise, Esperanza B. Papadopoulos, Jakob Passweg, Richard O’Reilly, Edouard Forcade, Molly Maloy, Liisa Volin, Hugo Castro-Malaspina, Yosr Hicheri, Ann A. Jakubowski, Corentin Orvain, Sergio Giralt, Mohamad Mohty…
    Citation: Journal of Hematology & Oncology 2018 11:127
    Content type: Research Published on:

  44. Hepatocellular carcinoma (HCC) is one of the most common tumors in the world, and its mortality is still on the rise. Limited treatments and low chemotherapy sensitivity of HCC make new therapeutic strategies ...

    Authors: Feifei Liu, Yanning Liu and Zhi Chen
    Citation: Journal of Hematology & Oncology 2018 11:126
    Content type: Review Published on:

  46. Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study w...

    Authors: Xu Liang, Adrien Briaux, Véronique Becette, Camille Benoist, Anais Boulai, Walid Chemlali, Anne Schnitzler, Sylvain Baulande, Sofia Rivera, Marie-Ange Mouret-Reynier, Laurence Venat Bouvet, Thibaut De La Motte Rouge, Jérôme Lemonnier, Florence Lerebours and Céline Callens
    Citation: Journal of Hematology & Oncology 2018 11:124
    Content type: Research Published on:

  47. In spite of major advances in treatment, multiple myeloma (MM) is currently an incurable malignancy due to the emergence of drug-resistant clones. We previously showed that MM cells upregulate the transcriptio...

    Authors: Daniela N Petrusca, Denise Toscani, Feng-Ming Wang, Cheolkyu Park, Colin D Crean, Judith L Anderson, Silvia Marino, Khalid S Mohammad, Dan Zhou, Rebecca Silbermann, Quanhong Sun, Noriyoshi Kurihara, Deborah L Galson, Nicola Giuliani and G David Roodman
    Citation: Journal of Hematology & Oncology 2018 11:123
    Content type: Research Published on:

  48. The JAK inhibitor (JAKi) ruxolitinib is standard treatment for myelofibrosis (MF), but some patients are unresponsive. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI)...

    Authors: Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi and Francesco Passamonti
    Citation: Journal of Hematology & Oncology 2018 11:122
    Content type: Letter to the Editor Published on:

  49. Genetically modified T cells that express a chimeric antigen receptor (CAR) are opening a new frontier in cancer immunotherapy. CAR T cells currently are in clinical trials for many cancer types. Cytokine rele...

    Authors: Delong Liu and Juanjuan Zhao
    Citation: Journal of Hematology & Oncology 2018 11:121
    Content type: Review Published on:

  50. Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor rece...

    Authors: Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, Feng Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad and Jiuda Zhao
    Citation: Journal of Hematology & Oncology 2018 11:120
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us